Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma.

Jasmine C HuynhMay ChoArta MonjazebEbaa Al-ObeidiAmisha SinghKit TamFrances LaraAnthony MartinezLeslie GarciaEdward J Kim

Published in: Investigational new drugs (2023)

Combination BMS-986,205 and nivolumab showed a manageable safety profile with durable benefit as first-line therapy in a meaningful subset of advanced HCC patients.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
clinical trial
peritoneal dialysis
prognostic factors
study protocol
stem cells
mesenchymal stem cells
phase ii
bone marrow
cell therapy
patient reported
smoking cessation